PubMed

The effect of antiretroviral treatment of different durations in primary HIV infection.

Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher HC, Porter K; CASCADE Collaboration.

AIDS. 2008 Nov 30;22(18):2441-50.PMID: 19005267 [PubMed - indexed for MEDLINE]Related articles

Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice.

Touloumi G, Pantazis N, Stirnadel HA, Walker AS, Boufassa F, Vanhems P, Porter K; CASCADE Collaboration.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):492-8.PMID: 18989233 [PubMed - indexed for MEDLINE]Related articles

Periapical status and quality of root canal fillings and coronal restorations in a Greek population.

Georgopoulou MK, Spanaki-Voreadi AP, Pantazis N, Kontakiotis EG, Morfis AS.

Quintessence Int. 2008 Feb;39(2):e85-92.PMID: 18560646 [PubMed - indexed for MEDLINE]Related articles

Robustness of a parametric model for informatively censored bivariate longitudinal data under misspecification of its distributional assumptions: A simulation study.

Pantazis N, Touloumi G.

Stat Med. 2007 Dec 30;26(30):5473-85.PMID: 18058854 [PubMed - indexed for MEDLINE]Related articles

Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort.

Fidler S, Fox J, Touloumi G, Pantazis N, Porter K, Babiker A, Weber J.

AIDS. 2007 Jun 19;21(10):1283-91.PMID: 17545704 [PubMed - indexed for MEDLINE]Related articles

Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.

Touloumi G, Pantazis N, Antoniou A, Stirnadel HA, Walker SA, Porter K; CASCADE Collaboration.

J Acquir Immune Defic Syndr. 2006 Aug 15;42(5):554-61.PMID: 16868497 [PubMed - indexed for MEDLINE]Related articles

Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy.

Hatzakis AE, Touloumi G, Pantazis N, Anastassopoulou CG, Katsarou O, Karafoulidou A, Goedert JJ, Kostrikis LG.

AIDS. 2004 Nov 19;18(17):2261-7.PMID: 15577538 [PubMed - indexed for MEDLINE]Related articles

Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates.

Touloumi G, Pantazis N, Babiker AG, Walker SA, Katsarou O, Karafoulidou A, Hatzakis A, Porter K; CASCADE Collaboration.

AIDS. 2004 Aug 20;18(12):1697-705.PMID: 15280781 [PubMed - indexed for MEDLINE]Related articles

Changes in T cell receptor excision DNA circle (TREC) levels in HIV type 1-infected subjects pre- and post-highly active antiretroviral therapy.

Touloumi G, Pantazis N, Karafoulidou A, Mandalaki T, Goedert JJ, Kostrikis LG, Hatzakis A.

AIDS Res Hum Retroviruses. 2004 Jan;20(1):47-54.PMID: 15000698 [PubMed - indexed for MEDLINE]Related articles

Elevated serum levels of soluble immune activation markers are associated with increased risk for death in HAART-naive HIV-1-infected patients.

Sipsas NV, Sfikakis PP, Touloumi G, Pantazis N, Choremi H, Kordossis T.

AIDS Patient Care STDS. 2003 Apr;17(4):147-53.PMID: 12737638 [PubMed - indexed for MEDLINE]Related articles

Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load.

Kostrikis LG, Touloumi G, Karanicolas R, Pantazis N, Anastassopoulou C, Karafoulidou A, Goedert JJ, Hatzakis A; Multicenter Hemophilia Cohort Study Group.

J Virol. 2002 Oct;76(20):10099-108.PMID: 12239284 [PubMed - indexed for MEDLINE]Related articlesFree article